The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ORIC | +64.42% | -34.63% | -8.15% | -49% |
| S&P | +18.37% | +110.18% | +16.02% | +142% |
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Private investors agreed to spend $85 million to purchase the company's stock.
The company discontinued development of its lead clinical program.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.31M | -14.0% |
| Market Cap | $865.03M | 81.5% |
| Market Cap / Employee | $6.76M | 44.6% |
| Employees | 128 | 19.6% |
| Net Income | -$36.36M | -13.7% |
| EBITDA | -$38.75M | -8.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $75.86M | 52.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $3.27M | 18.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -40.62% | -4.9% |
| Return On Invested Capital | -37.28% | -4.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$31.32M | -20.7% |
| Operating Free Cash Flow | -$31.26M | -22.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.29 | 2.08 | 1.63 | 3.28 | 126.37% |
| Price to Tangible Book Value | 2.29 | 2.08 | 1.63 | 3.28 | 126.37% |
| Enterprise Value to EBITDA | -11.93 | -8.24 | -6.04 | -13.26 | 121.71% |
| Return on Equity | -46.0% | -54.7% | -48.5% | -43.8% | 12.97% |
| Total Debt | $3.12M | $9.36M | $3.21M | $3.27M | 18.16% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
